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Abstract  71 
 72 
Objective 73 
Several small case series identified KCTD7 mutations in patients with a rare autosomal 74 
recessive disorder designated progressive myoclonic epilepsy (EPM3) and neuronal ceroid 75 
lipofuscinosis (CLN14). Despite the name KCTD (potassium channel tetramerization domain), 76 
KCTD protein family members lack predicted channel domains. We sought to translate insight 77 
gained from yeast studies to uncover disease mechanisms associated with deficiencies in 78 
KCTD7 of unknown function. 79 
 80 
Methods 81 
Novel KCTD7 variants in new and published patients were assessed for disease causality using 82 
genetic analyses, cell-based functional assays of patient fibroblasts and knockout yeast, and 83 
electron microscopy of patient samples.  84 
 85 
Results 86 
Patients with KCTD7 mutations can exhibit movement disorders or developmental regression 87 
before seizure onset, and are distinguished from similar disorders by an earlier age of onset. 88 
Although most published KCTD7 patient variants were excluded from a genome sequence 89 
database of normal human variations, most newly identified patient variants are present in this 90 
database, potentially challenging disease causality. However, genetic analysis and impaired 91 
biochemical interactions with cullin 3 support a causal role for patient KCTD7 variants, 92 
suggesting deleterious alleles of KCTD7 and other rare disease variants may be underestimated. 93 
Both patient-derived fibroblasts and yeast lacking Whi2 with sequence similarity to KCTD7 94 
have impaired autophagy consistent with brain pathology.  95 
 96 
Interpretation 97 
Bi-allelic KCTD7 mutations define a neurodegenerative disorder with lipofuscin and lipid 98 
droplet accumulation but without defining features of neuronal ceroid lipofuscinosis or 99 
lysosomal storage disorders. KCTD7 deficiency appears to cause an underlying autophagy-100 
lysosome defect conserved in yeast, thereby assigning a biological role for KCTD7.  101 
 102 
 103 
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 104 
Introduction  105 
Autism, schizophrenia, dystonia, epilepsy and other disorders have been linked to several 106 
members of the gene family KCTD (potassium channel tetramerization domain).1-4 All KCTD family 107 
proteins have an N-terminal BTB domain that is most similar in sequence to voltage-gated potassium 108 
channel tetramerization (T1/BTB) domains, hence the name KCTD.5 However, KCTD proteins 109 
appear unlikely to form channels as they lack predicted transmembrane domains and any direct 110 
interaction with potassium channels remains uncertain. Although KCTDs could indirectly alter 111 
channel properties, the gene name is potentially misleading and has caused some diagnostic 112 
challenges with implied treatments for channelopathies.6 Patients with KCTD7 mutations have been 113 
diagnosed with progressive myoclonic epilepsy (EPM3),4, 7-12 neuronal ceroid lipofuscinosis 14 114 
(CLN14),13 or opsoclonus-myoclonus syndrome (OMS).14 We sought to further define the clinical 115 
syndrome resulting from KCTD7 deficiency, to distinguish deleterious from normal variants in the 116 
general population, and to assign a function to the uncharacterized KCTD7 protein based on insights 117 
gained from our studies of the related protein in yeast, Whi2.  118 
KCTD family proteins are relatively uncharacterized, but one common theme has begun to 119 
emerge. A subset of KCTD family proteins may be components of cullin 3 (CUL3) ubiquitin ligase 120 
complexes.15 CUL3 uses BTB-containing adaptor proteins from other protein families to recruit cargo 121 
proteins for ubiquitination. Several KCTD family proteins including KCTD7 have been reported to 122 
bind CUL3,13, 16 consistent with structure modeling for other KCTDs.15 In this capacity as potential 123 
cargo adaptors, several other KCTD family proteins have been suggested to target specific cargo 124 
proteins for degradation,1 although most await confirmation. A similar role for KCTD7 is consistent 125 
with lysosome pathway defects in several other EPM and CLN disorders,17, 18 and other 126 
neurodegenerative processes.19 However, the molecular and cellular consequences of KCTD7 127 
deficiency are not known. 128 
This project was prompted by our genome-wide yeast genetic screen that uncovered the 129 
KCTD-like BTB-containing protein Whi2 of Saccharomyces cerevisiae.5 Yeast Whi2 is reportedly a 130 
general stress response factor,20 and has a contested role in mitophagy.21, 22 Yeast Whi2 and 131 
autophagy regulator Atg6 (human Beclin 1) were identified in our screen for factors required to 132 
respond to low amino acid availability,5, 23 a condition known to induce catabolic processes such as 133 
autophagy in yeast and mammals.24 Because yeast Whi2 shares sequence similarity and a common 134 
domain architecture with human KCTD proteins,5 we sought to gain new insight into the disease 135 
mechanisms due to KCTD7 mutations. We found that both yeast Whi2 and human KCTD7 are 136 
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required for normal autophagy in low nutrients, further supported by the accumulation of lipid bodies, 137 
defective mitochondria and abnormal autolysosomes.  138 
 139 
Methods  140 
Patient data collection  141 
Clinicians were provided a form for deidentified data (Table S1, IRB exempt status).  142 
 143 
Electron microscopy  144 
Patient fibroblasts were fixed in 2.5% glutaraldehyde (EM grade; Electron Microscopy Sciences, 145 
Hatfield, PA) in 0.1 M sodium cacodylate buffer (pH 7.4) for 1 h at room temperature, and processed 146 
by the Yale University Electron Microscopy Core as described.25  147 
 148 
PCR verification of KCTD7 mutations in patient fibroblasts  149 
Genomic DNA for KCTD7 exon-2 of primary human fibroblasts was amplified from extracted DNA 150 
using 5’ Primer (TGGCACCAATCAGACCCCAGGGATTGAAGATGGAGCAGCCC) and 3’ 151 
Primer (CCCATTTATTAAATTTCATCAATATGCTATCTCCTCTTCTAGG), separated on 1% 152 
agarose gel, extracted using Qiagen Gel Extraction Kit, and sequenced at MacrogenUSA using the 5’ 153 
primer to verify patient mutations in these cell lines.  154 
 155 
Plasmids 156 
 Wild type KCTD7 ORF was PCR amplified (Invitrogen AccuPrime Pfx) from HEK293 cDNA 157 
(Qiagen RT Kit) and cloned into a pSG5-derived vector to create N-terminal tagged proteins. Coding 158 
changes were subsequently engineered into KCTD7 and CUL3 expression vectors and verified by 159 
Sanger sequencing. prPGK-GFP-ATG8 was engineered by replacing the ATG8 5’ regulatory region 160 
with the 5’ regulatory region of PGK. 161 
 162 
Mammalian autophagy assays  163 
Primary patient fibroblasts (derived from 3 mm axilla skin punch) were shipped/received live and 164 
maintained in DMEM, 10-20% FBS and pen/strep. Age- and passage-matched control human 165 
fibroblasts GM05757 and 498 (Corriel Institute) were maintained in parallel and KCTD7 expression 166 
was assessed by qRT-PCR. Subconfluent cells, passage 4-8, were plated in 12-well dishes 167 
(50,000/well). The next day were washed 1x with PBS before treating. For nutrient deprivation, cells 168 
were switched to EBSS or to RPMI1640 without L-glutamine, amino acids or glucose (US 169 
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Biologicals) supplemented with 5% dialyzed FBS (Thermo) with or without amino acids (R7131 170 
Sigma) and glucose (4.5 g/L, Gibco).  For lysate preparation, cells were washed with PBS, 171 
solubilized in lysis buffer (62.5 mM Tris-HCl, 2% SDS, 0.01% Bromophenol Blue, 10% glycerol, 172 
2% β-mercaptoethanol) with protease inhibitor cocktail (Thermo Scientific) and heated to 100°C for 173 
10 min before separation by 12% SDS-PAGE and transfer to PVDF. Immunoblots were performed 174 
using antibodies for LC3B (CST #2775 or 3868, 1:1000) and actin (MP Biologicals #691001, 175 
1:10,000) and visualized using a Bio-Rad ChemiDoc MP system and analyzed with ImageLab 5.0 176 
software.  177 
 178 
Immunofluorescence microscopy  179 
Kyoto HeLa cells (ATCC) were grown on 12 mm glass cover slips in DMEM, 10% FBS plus 180 
pen/strep, and transfected the next day with 150 ng total DNA using JetPRIME (VWR). At 16-18 h 181 
posttransfection, cells were fixed 10 min with 4% formaldehyde (Polysciences, Warrington, PA), 182 
permeabilized with 0.2% Triton X-100 in PBS, immunostained, mounted (Prolong Gold, Life 183 
Technologies) and viewed with a Zeiss AxioImager M2 (60x Olympus objective), Hamamatsu Orca 184 
R2 camera and Volocity Software, or an Applied Precision DeltaVision microscope and software 185 
(60x Olympus objective) with Hamamatsu Photonics camera.  186 
 187 
Co-immunoprecipitations 188 
N-terminal 3HA/3Flag-KCTD7 and 6Myc-cullin 3 (CUL3) expression vectors were transiently 189 
transfected into HEK-293 cells using BioT (Bioland Scientific) for 2 days. Cells were lysed in native 190 
lysis buffer containing AEBSF, pepstatin, and leupeptin, rotated for 60 min at 4 ºC, and remaining 191 
insoluble material was removed by centrifugation. Samples were normalized (A280 nm) and rotated 192 
at 4 ºC for 2 h with pre-equilibrated EZview Red anti-HA or anti-FLAG affinity gel (Sigma). Beads 193 
were washed 4 times in the same buffer and proteins eluted by boiling in SDS-PAGE sample buffer. 194 
Whole-cell lysates (WCL) and anti-HA precipitates (IP) were separated by SDS-PAGE, transferred to 195 
PVDF membranes and probed with antibodies against FLAG (F1804, Sigma), HA (12CA5, Roche), 196 
or α-tubulin (HRP-66031, Proteintech) and HRP-conjugated secondary antibodies. Proteins were 197 
detected with Pierce ECL Western Blotting Substrate, SuperSignal West Femto Maximum Sensitivity 198 
Substrate and autoradiography. 199 
 200 
Yeast autophagy assays 201 
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Yeast strains (BY4741) transformed with autophagy reporter plasmids were grown overnight in 202 
synthetic SCCSH medium, refed for 1 h in fresh SCCSH medium at 1 OD600/ml, washed once and 203 
switched to low amino-acid medium SCME as described.5 Cells corresponding to 2 OD600 units were 204 
collected, lysed for immunoblot analysis.5 205 
 206 
Results  207 
To better define the disorder caused by KCTD7 mutations, we identified 18 novel mutations 208 
in 15 patients (11 families) from several sequencing centers and institutions (Fig 1A). A total of 30 209 
novel KCTD7 variants from 37 new and published patients can be grouped into three protein regions, 210 
the N-terminal BTB domain, a C-terminal cluster and a less defined middle region (Fig 1B). All 37 211 
patients have homozygous or compound heterozygous variants in KCTD7 (23 missense, 3 stopgain 212 
and 4 frameshifts). However, their association with disease does not constitute proof of pathogenicity 213 
for each patient variant. To address this point, we first characterized the clinical syndrome. 214 
 215 
KCTD7 mutations are associated with a progressive neurodegenerative disorder  216 
Overt seizures mark the recorded age of onset for 76% of KCTD7 patients, many with 217 
accompanying developmental delays and movement disorders, predominantly ataxia, tremors and 218 
dyskinesia (Fig 1A). The remaining 24% first develop movement disorders or developmental delays 219 
prior to seizure onset. Genetic testing for KCTD7 variants at earlier ages could potentially identify 220 
more patients with movement disorders before seizure onset. Other prominent clinical features 221 
include the loss of normal developmental milestones achieved in early childhood, difficulty walking, 222 
loss of speech and fine motor skills, and severe cognitive decline. While EEG findings are often 223 
positive, brain MRI is typically normal at onset but may detect diffuse or focal brain atrophy after 224 
disease progression, for example as observed for new patient-1 (T64A/R211X) but not for new 225 
patient-2 (Table S1). Patient-2 underwent a complete corpus callosotomy at age 6.9 years, and was 226 
seizure-free for at least 18 months, with some improvement in motor control. All patients progressed 227 
to develop myoclonic epilepsy, and all with available data developed movement disorders. Most 228 
become wheelchair-bound and non-verbal, and 6 of 37 died at ages 3-18 years (Fig 1A, asterisks). 229 
The few ambulatory patients now in their 20’s (patients-9, -10 and -19) have significant motor and 230 
cognitive deficits and exhibit autism, obsessive compulsive disorder or schizophrenia, in addition to 231 
epilepsy (Table S1). 232 
 233 
Early onset without retinal degeneration distinguishes KCTD7 patients 234 
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Distinguishing KCTD7/EPM3 patients from related disorders is the early age of onset, 235 
consistent with published case reports (Fig 2). Average onset age for all 37 patients is ~17 months, 236 
range 5-24 months except one of a sibling pair lacking C-terminal residue W289 with disease onset 237 
reported at 36 months (patient-37) (Fig 1A). No gender bias is present for incidence (49% males) 238 
although males tended to be diagnosed at a younger age (mean onset 15.1 mo males, 19.1 mo 239 
females). This early onset age for KCTD7/EPM3 patients does not overlap with other early onset 240 
myoclonic epilepsies (EPM1A, EPM2, EPM4), with the exception of infantile CLN1 (onset 6-24 241 
months) caused by mutations in lysosomal enzyme PPT1 (Fig 2).26, 27 However, KCTD7 patients 242 
uniformly lacked the characteristic CLN1-associated retinal abnormalities at onset and associated 243 
blindness (Fig 1A).18, 26 These findings shift the age downward for considering the diagnosis of 244 
EPM3, which is typically diagnosed in childhood or adolescence. 245 
KCTD7 patients are also distinguished from other related disorders. They have more severe 246 
cognitive decline and earlier onset than patients with a BTB domain variant in Kv3.1/ KCNC1 (onset 247 
age 3-15yr),28 but a later average onset than infantile spasms due to autosomal dominant mutations in 248 
DNM1 (onset typically 4-7 months) or autosomal recessive mutations in TBC1D24 (GTPase-249 
activating ARF6-binding protein) that cause pleiotropic neurologic disorders with myoclonic seizures 250 
(median onset 2-3 months, often at birth) (Fig 2).29, 30  251 
 252 
Prevalence of patient KCTD7 mutations in the general population 253 
To address disease causality of KCTD7 variants found in new patients, family pedigrees were 254 
constructed for the 15 new patients, revealing all variants were inherited (Fig 3A). For all patients 255 
(except published patient-15), 57 unaffected family members with available data were either wild 256 
type (2 of 10 sequenced siblings) or heterozygous for patient mutations (41 parents, 8 siblings, and 1 257 
grandparent) based on sequence data, and 5 parents based on kinship records of consanguinity (Table 258 
S2). The gene damage index GDI-Phred value for KCTD7 (1.235, medium damage prediction) and 259 
the selective pressure assessed by the McDonald-Kreitman neutrality index (0.004, moderate 260 
purifying)31 are also consistent with a monogenic autosomal recessive disease with complete 261 
penetrance. However, cautious causality assignments may still be warranted for specific KCTD7 262 
variants given ~500-20,000 protein-altering variants per individual.32 263 
If all 30 KCTD7 variants are disease-causing, each is expected to be rare in the general 264 
population. In an effort to catalog normal genetic variation in healthy individuals, the exome 265 
aggregation consortium ExAC database of ~60,000 unrelated healthy individuals excluded cancer 266 
genomes and cohorts with severe pediatric diseases.32 Thus, most of the KCTD7 patient variants 267 
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listed at ExAC (10 of 14) are from previously unpublished patients (Table S2). Among all KCTD7 268 
variant alleles identified, T64A (patient-1, T64A/R211X) is the most frequent in ExAC, where it is 269 
reported in 9 individuals (0.010% to 0.019% allele frequency in European and African populations, 270 
respectively), and in 16 heterozygous individuals in the aggregate gnomAD database of ~130,000 271 
individuals (Fig 3B). However, this frequency is still rare and to date no homozygotes for any amino 272 
acid change in KCTD7 has been reported in healthy individuals.32 Some disease variants reported to 273 
cause other CLN disorders (e.g. autosomal recessive CLN1 and CLN6) were subsequently challenged 274 
because of their prevalence in the ExAC database; for example CLN6 variant R252H.33 However, 275 
this CLN6 variant remains a disease candidate as none of the 21 normal individuals with this variant 276 
is homozygous.33  277 
 278 
KCTD7 patient mutations cause altered protein behavior 279 
To acquire further evidence that the most prevalent KCTD7 variant T64A (patient-1) is 280 
pathogenic, we sought a functional assay. As KCTD7 has no established biochemical activities, we 281 
tested for altered subcellular localization as an alternative strategy. The N-terminal amino acids 1-149 282 
of wild type KCTD7 containing the BTB domain, when expressed in HeLa (or other) cells, forms 283 
unusual flowing filament-like structures of unknown relevance in the cytoplasm and forms similar 284 
smaller structures in the nucleus (Fig 4A). Taking advantage of these elaborate structures to 285 
distinguish the effects of patient mutations, we found that expression of T64A(1-149) abolishes these 286 
cytoplasmic structures and instead localizes predominantly in a nuclear ball-and-stick pattern (Fig 287 
4A). Two other BTB domain mutations from published patients cause other distinguishable 288 
morphologies. L108M (patients 11-13) increases the occurrence of mini-circles at filament termini 289 
(Fig 4A, arrows), and D115Y (patient-15, lacking family genetics) causes massive filament-like 290 
structures (Fig 4A), which is likely a cause or consequence of protein stabilization (Fig 4B). When 291 
co-expressed with CUL3, an E3 ubiquitin ligase component and reported binding partner of 292 
KCTD7,13, 16 both wild type and D115Y, and to a lesser extent L108M, were capable of recruiting 293 
CUL3 from its more diffuse localization to KCTD7 structures, except the T64A mutant that only 294 
rarely co-localizes with CUL3 in fuzzy nuclear spots (Fig 4C and D). Thus T64A, as well as L108M 295 
and D115Y are likely to alter KCTD7 function, consistent with functional-effect prediction 296 
algorithms PolyPhen2, SIFT and PROVEAN, and L108M and D115Y are predicted damaging by 297 
two of these algorithms (Table S2).  298 
Providing further evidence that patient mutations can alter interactions with CUL3, co-299 
immunoprecipitation assays revealed that the N-terminal BTB-containing region but not the C-300 
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terminus of KCTD7 is required for CUL3 interaction, consistent with a role for KCTD7 as a CUL3 301 
adaptor. Furthermore, the patient BTB domain mutations tested in full-length KCTD7 (R70W, 302 
L108M and likely R84Q) impair binding to CUL3 (Fig 4E).  303 
The only patients predicted to have functionally benign variants by PolyPhen2, SIFT and 304 
PROVEAN also have less debilitating disease (sibling patients-9/-10, Table S1). However, their 305 
nucleotide change corresponding to G105E (c.314G>A) is located at the exon2-intron junction and is 306 
predicted to affect normal splicing (SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer 307 
and Human Splicing Finder). Other KCTD7 patient variants have discordant functional predictions 308 
between the different algorithms (Table S2), reinforcing that pathogenicity predictions are inherently 309 
limited without 3D structures and functional biochemical assays.  310 
 311 
KCTD7 heterozygosity in other neurological disorders 312 
We also identified 16 novel heterozygous KCTD7 variants in 18 additional unrelated 313 
individuals with phenotypes related to bi-allelic KCTD7EPM3 patients. These heterozygous patients 314 
with predominantly unsolved disease etiologies (mean onset age 8.6 years) have neurological 315 
phenotypes including developmental delays, seizures, disease progression, movement disorders 316 
and/or intellectual disabilities (Table S3). Only one of these 18 variants occurs more frequently than 317 
T64A in the population (Y86H occurs in 53 normal heterozygotes).32 Two of the 18 are also found in 318 
EPM3 patients with bi-allelic KCTD7 mutations, R121L and R153H. However, any role for 319 
heterozygous KCTD7 variants as genetic modifiers is not known.  320 
Conversely, we cannot rule out the possibility that non-KCTD7 variants act as genetic 321 
modifiers of more complex traits affecting onset age or other variations between bi-allelic KCTD7 322 
patients. Patient-9 (G105E/G114E) also has a heterozygous pathogenic variant in GALC that is 323 
reported in patients with autosomal recessive, late onset neurodegenerative Krabbe disease, and a 324 
heterozygous variant of unknown significance (VUS) in ARID1A, a conserved gene responsible for 325 
autosomal dominant intellectual disability (Coffin-Siris syndrome). Patient-14 (R112C/R112C) has 326 
mutations in three other genes linked to epilepsy, including a homozygous predicted damaging VUS 327 
in the glutamate receptor GRIN2A. These and other noted variants in bi-allelic KCTD7 deficient 328 
patients (Table S1) are currently not predicted to be disease-related, but only on the basis that all 329 
were inherited from one heterozygous parent and therefore insufficient to cause disease. 330 
 331 
Evidence for lysosome-pathway defects without characteristic neuronal ceroid lipofuscinosis  332 
Page 12 of 38
John Wiley & Sons
Annals of Neurology
For Peer Review
 12
Electron microscopy analysis of a frontal lobe brain biopsy from new patient-1 333 
(T64A/R211X) at age 8 years revealed neuronal pathology (Fig 5A) that was absent in the brain of a 334 
neurologically normal 6.7 yr child (not shown). The prominent brain pathology in patient-1 was the 335 
electron-dense lipofuscin (lysosomes) (Fig 5A). Similar structures are commonly observed in normal 336 
aging brain but not in children. A potential feature of KCTD7 brain lipofuscin is the late 337 
autophagosome-like structures (Fig 5B-D, arrows) engorged with both electron-dense lysosomes and 338 
electron-lucent structures presumed to be lipid droplets (Fig 5A-D, arrowheads). Soft lipid droplets 339 
are compressed between lysosomes or bulging against a delimiting membrane (Fig 5C and D, 340 
arrowheads). Others have observed similar structures in autophagy-deficient cells, and in cells 341 
overfed with oleic acid.34 The persistence of lipid droplets in brain tissue could potentially reflect an 342 
underlying defect related to lipophagy, a form of autophagy that is required for utilization of lipid 343 
stores as an energy source and that requires components of the autophagy pathway.35 344 
Bi-allelic KCTD7 mutations that define a diagnosis of EPM3, also define the diagnosis of 345 
neuronal ceroid lipofuscinosis 14 (CLN14) based on a study of patient-24 (R184C/R184C).13 That 346 
study reported characteristic ultrastructural features of fingerprint-like profiles and granular 347 
osmiophilic deposits (GROD) in fibroblasts and neurons from a skin biopsy and in lymphocytes.13, 36 348 
However, we did not observe these or other features considered to be characteristic of neuronal 349 
ceroid lipofuscinosis, such as cytosomes, rectilinear profiles (RLP) or curvilinear morphologies 350 
described for other CLN subtypes.36 Clinical records indicate that new patient-1 also lacked such 351 
ultrastructural features in lymphocytes, skin and rectal biopsy histology, recommended sites for 352 
detection of neuronal ceroid lipofuscinosis.36 Although detection can be challenging,36 electron 353 
microscopy and/or light microscopy of skin and muscle biopsies from published patients-4, 5, 11, 15, 354 
26, and 30/31,7, 8, 11 as well as new patients-1, 20, 22 and 28 also lack these specific features (Table 355 
S1). In addition, no storage material resembling other lysosomal storage disorders was detected in 356 
neurons, vascular endothelial or smooth muscle cells of patient-1. Broader diagnostic criteria may be 357 
needed to include KCTD7 as a CLN disorder.   358 
Cultured skin fibroblasts naturally lack some of the lysosomal substrates enriched in the brain 359 
such as specific glycosphingolipids, and are therefore not expected to reveal some brain pathologies. 360 
However, fibroblast cultures are useful for evaluating other autophagosome-lysosome functions and 361 
ultrastructure. In contrast to an age- and passage-matched control, prominent features of early-362 
passage skin-derived fibroblast cultures from patient-3 and patient-4 with BTB domain mutations 363 
include the supernumerary lipid droplets often in close proximity to mitochondria and ER (Fig 6A). 364 
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Some lipid droplets appeared to be engulfed in membrane-bound structures (Fig 6A, arrowheads), 365 
reminiscent of the lipid droplets in patient brain, possibly suggesting a stalled catabolic process. 366 
Other prominent features that distinguish both patient fibroblasts from age- and passage-367 
matched control fibroblasts include hybrid structures resembling late single-membrane or partially 368 
double-membrane autolysosomes.37 These hybrid structures contain local electron-densities typical of 369 
lysosomes (Fig 6B, black arrows) that are associated with larger autophagosome-like structures 370 
containing residual undegraded material (Fig 6B, white arrows) and occasional electron dense lipid 371 
whirls (Fig 6B). Similar hybrid structures are also characteristics of diverse neurodegenerative 372 
disorders including mucolipidosis type IV, Alzheimer’s disease, CLN types and autophagy-deficient 373 
cell lines.37-39  374 
Although mitochondrial organelles were not sufficiently preserved in patient biopsy 375 
preparations, most cultured fibroblasts from both patients contained a fraction of mitochondria with 376 
internal, closed double membrane structures presumed to reflect cristae malformations (Fig 6C). 377 
These malformations are somewhat reminiscent of mitochondria in mitofilin-deficient cells with 378 
concentric cristae.40 Ultrastructural abnormalities were prevalent in patient cells but absent in control 379 
cells (Fig 6D). The apparent accumulation of several abnormal organelles in patient-derived 380 
fibroblasts and in a brain biopsy is consistent with a defect in the phagolysosome pathway.  381 
 382 
Conserved autophagy defects as a potential mechanism of disease pathogenesis 383 
We initiated this KCTD7 project based on insights gained from studying the poorly 384 
characterized yeast protein Whi2, which shares sequence similarity with KCTD7 and harbors a 385 
homologous BTB structural domain.5 Yeast lacking WHI2 are sensitive to multiple cell stresses and 386 
fail to halt the cell cycle in response to low amino acid levels in the media, conditions known to 387 
induce autophagy.5, 20, 23 Taken together with our ultrastructural findings in patient samples, we asked 388 
if whi2-deficient yeast have a general autophagy defect using an established reporter for yeast Atg8,41 389 
homolog of mammalian autophagy marker LC3. In low amino acid medium, the autophagy-390 
responsive ATG8 promoter is induced to express the reporter, and during autophagy flux undergoes 391 
lysosomal/vacuolar processing that cleaves the protease-sensitive Atg8 moiety from the more stable 392 
GFP protein in wild type cells.41 In striking contrast to wild type, whi2-deletion strains are profoundly 393 
defective for autophagy induction and flux (Fig 7A). Similar but less dramatic results were obtained 394 
with an autophagy flux-specific reporter expressed by the constitutive PGK promoter, indicating that 395 
Whi2 is required for normal autophagy induction and flux after switching to low amino acids (Fig 7 396 
B). This autophagy defect was not due to a general defect in reporter expression or global protein 397 
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translation, as free GFP expressed via an autophagy-independent promoter (ADH1) was expressed 398 
indistinguishably in wild type and whi2-deficient yeast (Fig 7C). 399 
To extend these findings from yeast, the skin-derived fibroblast lines from patients-3 and -4 400 
with BTB domain mutations were analyzed for autophagy defects. The accumulation of endogenous 401 
lipidated/mature LC3-II following treatment with chloroquine to inhibit lysosome function that 402 
otherwise degrades LC3-II.42 Consistently, LC3-II accumulated less efficiently in low-passage patient 403 
fibroblasts versus age- and passage-matched controls following chloroquine treatment to assess basal 404 
autophagy flux (Fig 8A and B), and when autophagy was induced by withdrawing amino acids and 405 
glucose (Fig 8B and C). Autophagy induced by more severe starvation was also significantly lower 406 
in patient fibroblasts assessed by conversion of LC3I to LC3II (Fig 8E). Thus, both WHI2-deficient 407 
yeast and patient cells have a defect in autophagy based on Atg8/LC3 assays following nutrient 408 
depletion. To confirm the origins of our fibroblast cell lines, genomic DNA isolated from patient and 409 
control cells used in these studies was sequenced, revealing the expected variants for patients-3 and -410 
4. 411 
The functional consequences of autophagy deficiency were assessed by determining the 412 
effects of KCTD7 on neurite outgrowth triggered by serum withdrawal in mouse neuroblastoma N2a 413 
cells. The maturation of N2a cells to produce extensive neuron-like processes requires autophagy, as 414 
knockdown of conserved Beclin 1/Atg6 blocks neurite extension.43 We found that partial knockdown 415 
of endogenous mouse Kctd7 severely reduces neurite outgrowth triggered by serum withdrawal, 416 
indicating a critical role for KCTD7 in neurite maturation (Fig 8F and G). 417 
 418 
Discussion 419 
Manifestations of KCTD7 mutations 420 
Guided by our findings in yeast, we investigated the clinical and cellular consequences of 421 
KCTD7 mutations. Bi-allelic KCTD7 mutations cause an early onset (16.8±6 months) progressive 422 
myoclonic epilepsy previously ascribed only to older children.17, 18 These patients are characterized 423 
by movement disorders and developmental delays that may precede onset of intractable myoclonic 424 
seizures more often than appreciated based on recorded parental comments. The few ambulatory 425 
patients exhibit severe cognitive and psychosocial impairments. All patients exhibit disease 426 
progression indicative of an underlying degenerative process despite apparently normal initial 427 
developmental milestones. Ultrastructural analysis of a brain biopsy or skin fibroblasts from a total of 428 
three different patients revealed shared features, most notably the accumulation of lipid droplets and 429 
abnormal phagolysosomes containing undegraded material. Misshapen mitochondrial cristae 430 
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membranes were also prominent features of skin fibroblasts where sample preparation is more 431 
amenable to organelle preservation (Figs 5 and 6). The constituents of lipofuscin granules in patient 432 
brain appear to be residual bodies derived from lysosomes and could potentially be produced by a 433 
partial degradation of unsaturated lipids. Brain biopsies for future patients may provide more 434 
valuable information. The ultrastructural features in patient samples together with defective 435 
autophagy responses in patient fibroblasts and the corresponding yeast deletion strain are consistent 436 
with the possibility that an autophagy-lysosome pathway defect underlies the disease caused by bi-437 
allelic KCTD7 mutations. Although lysosome pathway defects are implicated in a growing number of 438 
neurological disorders, each can manifest differently, presumably owing to the molecular details not 439 
yet known. New therapies will be needed that enhance autophagosome-lysosome function without 440 
worsening defective bottlenecks downstream in the pathway. 441 
Two reported phenotypes for KCTD7/EPM3 patients were not found in the new patient cohort 442 
reported here. Clonic eye movements reported for patient-3 diagnosed with opsoclonus-myoclonus 443 
syndrome (OMS)14 were not detected though not formally tested. We also did not detect specific 444 
neuronal ceroid lipofuscinosis pathology reported for patient-24, the founder case for CLN14 445 
designation, although this patient potentially had more severe disease (onset 8 mo, died 17 yr).13  446 
 447 
Causality of KCTD7 variants 448 
The low frequency in the general population of each of the 30 unique KCTD7 patient variants, 449 
including T64A, and the lack of homozygous patient variants in healthy individuals,32 indicate that 450 
these 30 variants are causal for EPM3/CLN14. This disorder occurs worldwide and the patients in 451 
this study have diverse ancestry (e.g. Moroccan, Syrian Sephardi, European, Native American, 452 
French Canadian). Genome sequence data from the general population suggest at least 0.05% of 453 
healthy unrelated individuals may carry a heterozygous pathogenic KCTD7 variant.32 The relatively 454 
higher than average arginine content of the KCTD7 protein (7.3% vs. 4-6%) may contribute to the 455 
mutation frequency (12 of 30 variants change an Arg, Table S1) given that arginine codons have the 456 
highest proportion of CpG sequences and CpG mutations (affecting DNA methylation) are by far the 457 
most prevalent in the population.32   458 
Additional rare heterozygous KCTD7 variants were identified in 17 additional patients with 459 
related yet clinically distinct disorders (Table S3), although any contribution to disease is unknown. 460 
However, when considering the genetic complexities of neurobehavioral disorders such as autism, 461 
other genetic modifiers with discernable clinical phenotypes may exist. KCTD7 sibling patients-9/10 462 
were diagnosed with autism. The KCTD7-related KCTD13 gene at 16p11.2 is thought to have a role 463 
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in a small subset of autism cases.1 Any manifestations of heterozygous KCTD7 mutations in late 464 
onset disorders analogous to heterozygous loss of progranulin in older adults with frontotemporal 465 
dementia/FTD versus bi-allelic mutations that cause lipofuscinosis CLN1144 are unexplored. Based 466 
on yeast studies that first identified the KCTD-like yeast Whi2,5 KCTD7 variants could potentially 467 
compensate for more deleterious mutations. Spontaneous mutations in the analogous gene WHI2 can 468 
compensate in part for the more detrimental lack of mitochondrial fission factor Fis1 or several other 469 
genes.5, 23   470 
 471 
Biological and biochemical roles for KCTD7  472 
The biochemical function of KCTD7 is not known and little is understood about the other 24 473 
human family members (KCTD1-21, TNFAIP1, KCNRG, SHKBP1 and BTBD10). Inspired by our 474 
finding that yeast Whi2 is required to suppress cell growth in low amino acid conditions,5, 23 it was 475 
reasonable to consider that whi2-deficient yeast were also defective for autophagy induction. 476 
Therefore, we tested for an evolutionarily conserved function between Whi2 and KCTD7 in 477 
autophagy. We found that both yeast Whi2 and KCTD7 are required for normal basal autophagy and 478 
low nutrient-induced autophagy (Figs 7 and 8). Both yeast Whi2 and the KCTD7 homolog, KCTD11, 479 
were recently shown to suppress TORC1/mTORC1, a known inhibitor of autophagy.45  The same 480 
study failed to detect an effect of KCTD7 on TORC1/mTORC1 activity in yeast and primate COS7 481 
cells. However, a role for KCTD7 in autophagy-lysosome function is consistent with our 482 
ultrastructural studies revealing abnormal autophagosome-lysosome structures, mitochondrial cristae 483 
and supernumerary lipid droplets potentially reflecting impaired lipophagy (Fig 5 and 6). Related 484 
pathologies are observed with aging-related lysosomal dysfunction and progressive decline in 485 
chaperone-mediated autophagy rates in late-onset Alzheimer disease,37 perpetuated by oxidation of 486 
partially degraded macromolecules derived from mitochondria, glycosphingolipids and other 487 
components in autolysosomes resulting in reactive oxygen species that interact with lysosomal iron.46  488 
Consistent with our finding of abnormal mitochondrial cristae in patient-derived cells, one 489 
study investigated the role of yeast Whi2 in mitophagy (a subtype of autophagy). They reported that 490 
the spontaneous WHI2 mutation in FIS1 knockout strains, rather than loss of the FIS1 mitochondrial 491 
fission gene, causes a defect in the degradation of yeast mitochondrial organelles.21 However, a 492 
subsequent study challenged this conclusion, reporting that mitochondrial fission mediated by FIS1 493 
rather than WHI2 is required for normal mitophagy.22 Thus, the question remains open.   494 
A possible role for KCTD7 in protein turnover is consistent with having an N-terminal BTB 495 
domain, where almost half of the patient mutations identified thus far occur (Fig 1B), as BTB 496 
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proteins can serve as adaptor proteins that retrieve substrates for the CUL3 ubiquitin ligase complex. 497 
47 Interesting, several other KCTD family members were identified in screens for cullin-ARIH1 498 
complex components,48 consistent with serving as an E3 ubiquitin ligase adaptor. CUL3 has many 499 
critical roles in cells, and a role for CUL3 in autophagy has gained recent attention. CUL3 and its 500 
BTB-Kelch adaptor protein KLHL20 were found to prevent overzealous autophagy by direct 501 
ubiquitination and degradation of ULK1, a key upstream positive regulator of autophagy induction.49 502 
Although KCTD family proteins have not been demonstrated to have a molecular role in autophagy, 503 
defective autophagy-lysosome pathways are consistent with their causal roles in neurodegenerative 504 
disorders.   505 
 506 
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Figure Legends 645 
Fig 1. Genetics and clinical features for all KCTD7 patients.  646 
(A) KCTD7 protein changes and clinical features for 37 new and published patients numbered by 647 
KCTD7 variant position and color-coded by protein region as in panel B. Initial DNA sequencing 648 
strategies: whole genome (WGS), whole exome (WES), clinical diagnostic sequencing panel (DSP), 649 
genome-wide linkage/autozygosity mapping (GWL), Sanger sequencing (Sngr), and the heat map of 650 
clinical features for all new patients are derived from deidentified clinical data (Table S1) and from 651 
published cases as cited by reference number.4, 7-11, 13, 14 Note, L108M patient 13 was confirmed by 652 
the authors to be distinct from patients-11 and -12. Estimated age of onset (months) for males vs. 653 
females is not significant, p=0.055 (two-tailed t-test). *Deceased. (B) Map of human KCTD7 654 
isoform-1 (289 amino acids) encoded on 4 color-shaded exons (scale units = 10 residues); 30 patient 655 
variants are grouped in color-coded clusters as in panel A. BTB domain (transparent box); missense 656 
mutations (solid line), nonsense mutations (dashed), frameshift (double line), mutations occurring in 657 
>1 family (diamond), different amino acid mutation at the same position in >1 family (square). 658 
   659 
Fig 2. Earlier disease onset distinguishes KCTD7/EPM3 from other myoclonic epilepsies.  660 
Range (bars) and median (line) age of disease onset for early-onset disorders with myoclonic seizures. 661 
TBC1D24 calculated from Supplementary data in Balestrini et al.,29 DNM1,30 CLN1/CLN3,17 662 
KCNC1,28 MERRF,50 EPM1A/EPM2/EPM4,27 sialidosis/mucolipidosis-I 663 
https://emedicine.medscape.com/article/948704-overview, and for KCTD7/EPM3 from Fig 1A.  664 
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 665 
Fig 3. KCTD7 family pedigrees and mutation frequency. 666 
(A) Pedigrees of 11 new families from Fig 1A with 18 novel KCTD7 variants in 15 bi-allelic patients; 667 
birth order unknown for family 12. (B) All patient variants listed in the ExAC32 and gnomAD 668 
sequence databases http://gnomad.broadinstitute.org/ for the correct KCTD7 transcript 669 
ENST00000275532 (Table S2).  670 
 671 
Fig 4. Patient mutations in the BTB domain affect cullin 3 (CUL3) interactions.  672 
(A) Immunofluorescence microscopy of N-terminal HA-tagged KCTD7-BTB (amino acids 1-149) in 673 
Kyoto HeLa cells transfected 18 h and stained with 1:1000 anti-HA (Santa Cruz HA Y-11) and 674 
1:2000 anti-Myc (Calbiochem Ab-1 OP10L) (similar results without tag and in other cell types 675 
tested). Representative of >3 independent experiments. (B) Immunoblots (12% SDS-PAGE, PVDF) 676 
of samples described for panels A, C and D probed for anti-HA (1:1000; Santa Cruz Y11), anti-Myc 677 
(1:2000; Calbiochem), and anti-actin as loading control (1:10,000; MP Biomedicals 691001), 678 
representative of two independent experiments each with both WT and inactive K712R mutant CUL3 679 
yielding similar results. (C) Immunofluorescence microscopy of Kyoto HeLa cells transfected with 680 
N-terminal 6Myc-tagged CUL3 (K712R) alone and detected with anti-Myc (similar results for wild 681 
type 6Myc-CUL3). (D) Parallel samples to panels B and C co-transfected with HA-KCTD7(1-149) 682 
and N-terminal 6Myc-cullin3(K712R) and dual-stained with anti-Myc and anti-HA. Individual gray 683 
scale and color merged immunofluorescence microscopy images shown. Representative of >3 684 
independent experiments per condition. Scale bar = 10 µm in all panels. (E) Co-immunoprecipitation 685 
of WT 6Myc-Cul3 from HEK293 whole cell lysates (WCL) after transient co-transfection with 3His-686 
3Flag-KCTD7 using anti-Flag M2 affinity matrix for immunoprecipitation (IP). The strength of the 687 
interaction between CUL3 and KCTD7 variants was quantified as a ratio of the IP cMyc signal to the 688 
IP Flag signal and normalized to the WT KCTD7/CUL3 ratio in the total IP. Representative of 3 689 
independent experiments is shown. **P<0.000001, *P<0.03 690 
 691 
Fig 5. Abnormal phagolysosomes with lipid droplets in patient brain biopsy.  692 
A-D. Electron micrographs of frontal lobe brain biopsy from patient-1 (T64A/R211X) at age 8 years. 693 
Electron-dense lipofuscin (lysosome) structures typically contain electron-lucent lipid droplets 694 
(arrowheads) that may be encased within the delimiting membrane (arrow) of phagosome-like 695 
structures also containing lysosomes, but no curvilinear, fingerprint inclusions, GROD or other 696 
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characteristics of neuronal ceroid lipofuscinosis (NCL). Images presented are from two independent 697 
preparations. 698 
 699 
Fig 6. Lipid droplets and abnormal phagolysosomes and mitochondria in patient fibroblasts. 700 
Electron microscopy of low (~6) passage cultured skin fibroblasts taken from patients-3 and -4 at 701 
ages 4 years and 6 years, respectively. (A) Supernumerary lipid droplets (LD) near mitochondria (m) 702 
common to both patients unlike age/passage-matched controls not depicted. LDs engulfed in 703 
membrane-bound structures (white arrowheads); normal caveolae pits and caveolae vesicles typical 704 
of normal healthy fibroblasts (patient-3, top). (B) Abnormal membrane-bound lysosome structures 705 
(black arrows) associated with larger single or partial double membrane phagosome-like 706 
compartments sparsely filled with lightly-stained undegraded material (white arrows) and occasional 707 
electron-dense lipid whirls (example in left and right panels); lipid droplets (LD) detected in all 3 708 
panels; swollen endoplasmic reticulum (ER, right panel). (C) Age- and passage-matched control 709 
fibroblasts 5757 (left panel) lack abnormal mitochondria (m) containing double membrane structures 710 
(black arrowheads) common to both patient fibroblasts. (D) Quantification of abnormal morphologies 711 
presented as the percent of randomly selected cells (n=33, patient-3) and (n=39, patient-4), and ~100 712 
fields of control 5757. Cells with supernumerary LDs typically contain over 100 LDs often close to 713 
mitochondria. 714 
 715 
Fig 7. Defective autophagy in whi2-deficient yeast.  716 
(A) Immunoblots of wild type and whi2 knockout strains of Saccharomyces cerevisiae (BY4741) 717 
expressing autophagy reporter fusion protein GFP-Atg8 expressed by autophagy-responsive yeast 718 
ATG8/LC3 promoter (pr), before and after switching from high to low amino acid medium as 719 
described,5, 23 probed with 1:1000 anti-GFP (Santa Cruz sc-9996), loading control anti-Pgk 720 
 (Abcam 113687), and HRP-conjugated secondary antibodies (GE Healthcare, 1:20,000). Induction 721 
of the ATG8 promoter (total GFP in upper+lower bands relative to PGK loading control) and 722 
autophagy flux (protease-resistant free GFP liberated by vacuolar protease-dependent digestion of the 723 
Atg8 moiety relative to total GFP) are presented in separate graphs as mean +/-SD for 3 independent 724 
experiments with/without switching to low amino acids. (B) Experiment and analysis as described for 725 
panel A except using the constitutive PGK promoter (pr) to express the GFP-Atg8 autophagy reporter. 726 
For panels A and B, results are presented as mean+/-SD for 3 independent experiments. Two-tailed t-727 
test: WT vs. ∆whi2, *p<0.05, **p<0.005, ***p<0.001). (C) As described in panel A except using the 728 
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transcription/translation control GFP reporter (no Atg8) expressed by the constitutive ADH1 729 
promoter, probed with anti-GFP and loading control anti-Cdc11 (Novus Biologicals NB100-81019).  730 
 731 
Fig 8. Conservation of autophagy defect in KCTD7 patient fibroblasts. 732 
(A) Immunoblot of control age-/passage-matched human fibroblasts and fibroblasts derived from 733 
patient-3 and -4 (passage 6-8) for endogenous autophagy protein LC3 (1:1000 anti-LC3, Cell 734 
Signaling 2775) and HSP90 loading control (BD Biosciences 610419) detected with HRP-conjugated 735 
secondary antibodies (GE Healthcare, 1:20,000), developed using ECL-Prime (GE Healthcare). 736 
Compare LC3-II levels before versus after 1 h with 15 µM chloroquine (Sigma C6628) or carrier 737 
control to assess basal autophagy (arrows). (B) Quantified data for panel A, pooling 5757 and 498 738 
control cells versus patient cells from 3 independent experiments, each performed in duplicate or 739 
triplicate for each of the 4 cell lines (n=11 per condition) and presented as the ratio of LC3-II levels 740 
+/-15 µM chloroquine after correcting for loading; mean+/-SE, 2-tailed t-test, p = 0.00065. (C) 741 
Autophagy assay as in panel A except cells were treated 3 h +/-glucose, +/-amino acids, +/-100 nM 742 
Bafilomycin A1 (Enzo). (D) Quantification for panel C presented as mean+/-SE of LC3-II levels 743 
adjusted to relative loading controls and calculated as the fold change over control 5757 in full 744 
medium for 6-8 replicates in 4 independent experiments. Two-tailed t-test, *p<0.05. (E) Autophagy 745 
assay as in panel A except cells were incubated in amino acid-free/serum-free Earle’s balanced salt 746 
solution (Thermo Fisher). The change in LC3-II/LC3-I ratios relative to time 0 is presented as 747 
mean+/-SE for 3 independent experiments; 2-tailed t-test for control-5757 vs. patient-3 at 2 h and 3 h 748 
(p=0.002 and p=0.018), and patient-4 (p=0.023 and p=0.020, respectively). (F) Light microscopy 749 
(Nikon TE200) of control and mouse Kctd7-specific shK7.1 shRNA knockdown (TRCN0000069304 750 
transfected with FuGENE or Lipofectamine2000) in N2a mouse neuroblastoma cells refed +/-serum 751 
48 h to monitor neurite outgrowths (arrows). (G) Immunoblot confirmation of endogenous Kctd7 752 
knockdown by shK7.1 with 1:1000 anti-KCTD7 (Abcam ab83237) and anti-HSP90 (BD Biosciences 753 
610419) loading control. Lysates and immunoblots were prepared as described for panel A, except 754 
visualized using Amersham Hyperfilm ECL (GE Healthcare). 755 
 756 
Supporting Materials  757 
Table S1. Supporting clinical data 758 
Table S2. KCTD7/EPM3 genetic data 759 
Table S3. KCTD7 heterozygous variant data 760 
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